151276-95-8|KRN 5500|(2E,4E)-N-(2-(((2R,3R,4R,5R,6S)-6-((7H-purin-6-yl)amino)-2-((S)-1,2-dihydroxyethyl)-4,5-dihydroxytetrahydro-2H-pyran-3-yl)amino)-2-oxoethyl)tetradeca-2,4-dienamide|-范德生物科技公司

KRN 5500

NMR下载 COA and HPLC MSDS下载
names：
(2E,4E)-N-(2-(((2R,3R,4R,5R,6S)-6-((7H-purin-6-yl)amino)-2-((S)-1,2-dihydroxyethyl)-4,5-dihydroxytetrahydro-2H-pyran-3-yl)amino)-2-oxoethyl)tetradeca-2,4-dienamide
CAS号：
151276-95-8
MDL Number：
MF(分子式)： C28H43N7O7 MW(分子量)： 589.69
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	KRN 5500
英文别名	SPK-241; KRN-5500; NSC-650426; SPK241; KRN5500; NSC650426; SPK 241; KRN 5500; NSC 650426
CAS号	151276-95-8
Inchi	InChI=1S/C28H43N7O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-19(38)29-14-20(39)34-21-23(40)24(41)28(42-25(21)18(37)15-36)35-27-22-26(31-16-30-22)32-17-33-27/h10-13,16-18,21,23-25,28,36-37,40-41H,2-9,14-15H2,1H3,(H,29,38)(H,34,39)(H2,30,31,32,33,35)/b11-10+,13-12+/t18-,21+,23+,24+,25-,28-/m0/s1
InchiKey	LQIPDFIUPOYMPR-BKYURJJWSA-N
分子式 Formula	C28H43N7O7
分子量 Molecular Weight	589.69
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	KRN 5500(CAS:151276-95-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	KRN 5500 is a derivative of the nucleoside antibiotic spicamycin with a wide range of antitumor activity against human cancer cell lines.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kawai H. [Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1571-7. Review. Japanese. PubMed PMID: 9309156.

[2]Weinstein SM, Abernethy AP, Spruill SE, Pike IM, True Kelly A, Jett LG. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial. J Pain Symptom Manage. 2012 Apr;43(4):679-93. doi: 10.1016/j.jpainsymman.2011.05.003. PubMed PMID: 21983265.

[3] Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PubMed PMID: 15148527.

[4] Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.

[5] Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PubMed PMID: 14685303.

6: Miki H, Ozaki S, Nakamura S, Oda A, Amou H, Ikegame A, Watanabe K, Hiasa M, Cui Q, Harada T, Fujii S, Nakano A, Kagawa K, Takeuchi K, Yata K, Sakai A, Abe M, Matsumoto T. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts. Br J Haematol. 2011 Nov;155(3):328-39. doi: 10.1111/j.1365-2141.2011.08844.x. PubMed PMID: 21902681.7: Mizumura Y. [Spicamycin derivative]. Nihon Rinsho. 2006 Feb;64(2):322-8. Review. Japanese. PubMed PMID: 16454188.8: Yokoyama M, Satoh A, Sakurai Y, Okano T, Matsumura Y, Kakizoe T, Kataoka K. Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. J Control Release. 1998 Nov 13;55(2-3):219-29. PubMed PMID: 9795065.9: Byrd JC, Lucas DM, Mone AP, Kitner JB, Drabick JJ, Grever MR. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood. 2003 Jun 1;101(11):4547-50. PubMed PMID: 12595316.10: Supko JG, Eder JP Jr, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003 Nov 1;9(14):5178-86. PubMed PMID: 14613997.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开